We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




African-American MS Patients Experience More Rapid B-Cell Repopulation

By LabMedica International staff writers
Posted on 06 May 2021
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). More...
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of the body.

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, but the interval between attacks may be weeks, months or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).

Medical Scientists from the NYU Grossman School of Medicine (New York, NY, USA) enrolled in a retrospective cross-sectional study, 168 patients, including 61 African-American patients, 60 white patients, and 47 who identified as other races; about 19% were Hispanic. About 80% of the patients were diagnosed with multiple sclerosis, and 19% had neuromyelitis optica spectrum disorder. The team also looked at the types of B cells being repopulated and found there were no differences between African-Americans and whites in the makeup of the cells.

The team reported that in the 6 to 12 months after undergoing treatment with rituximab or ocrelizumab to deplete B cells, African-Americans patients were more than twice as likely to have B cell repopulation compared with white patients (76% versus 33%). In the four to six months following treatment, however, repopulation of B cells was about the same in both groups, at roughly 21% in the African-American patients compared with 18% in the white patients. No patients had B cell repopulation within four months of treatment. At four to six months, 23% had B cell repopulation and by after 10 months, 90% had repopulation of their B cells.

Lucia Saidenberg, MD, an author of the study, said, “Anti-CD20 therapy, including rituximab and ocrelizumab, are highly effective treatments for multiple sclerosis and neuromyelitis optica spectrum disorder and are known to cause a near complete depletion of B cells in the blood soon after infusion. However, repopulation of B cells following anti-CD20 infusion has not been well studied in these patients, particularly not in African-American patients, who are underrepresented in clinical trials for these drugs and tend to have more severe disease and faster disease progression compared to white patients with multiple sclerosis.” The study was presented at the American Academy of Neurology virtual meeting held April 17-22, 2021.

Related Links:
NYU Grossman School of Medicine


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.